Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model

International Journal of Cancer

Volumn 100, Issue 5, 2002, Pages 615-617

  Middleton, Mark R ^a   Thatcher, Nicholas ^a   Brian H McMurry, T ^b   Stanley McElhinney, R ^b   Donnelly, Dorothy J ^b   Margison, Geoffrey P ^c,d  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

ATase; Methylating agents; MGMT; O6 methylguanine; Pseudosubstrates

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE INHIBITOR; ALKYLATING AGENT; GUANINE DERIVATIVE; LOMEGUATRIB; NITROSOUREA DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE; DACARBAZINE; DRUG DERIVATIVE; GUANINE; O(6) (4 BROMOTHENYL)GUANINE; O(6)-(4-BROMOTHENYL)GUANINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER RESISTANCE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INACTIVATION; ENZYME SUBSTRATE; MALE; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; WEIGHT REDUCTION; XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL DIVISION; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; PATHOLOGY; TIME;

ADENOSINE TRIPHOSPHATASES; ANIMALS; CELL DIVISION; DACARBAZINE; DISEASE MODELS, ANIMAL; GUANINE; HUMANS; MALE; MELANOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TIME FACTORS;

EID: 0037055378     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10532     Document Type: Article

References (21)

1. A randomized, phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced, metastatic melanoma
2. Biological consequences of reactions with DNA: Role of specific lesions
3. Detection mismatch binding and a mutator phenotype in cells tolerant to DNA damage
4. In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukaemia sensitive and resistant to chloroethylnitrosoureas
5. 6-alkylguanine alkyltransferase (AT) in cancer chemotherapy
6. Transfection of murine multi-potent haemopoietic stem cells with an E. coli DNA alkyltransferase gene confers resistance to the toxic effects of alkylating agents
7. 6-alkylguanine-DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents
8. 6-methylguanine as a free base
9. 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents
10. Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts
11. 6-methylguanine formation, repair protein depletion and clinical outcome with a 4-hourly schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study
12. 6-(4-bromothenyl)-guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts
13. Drug resistance in human melanoma
14. Alterations of Fas (Apo-I/CD95) gene in cutaneous malignant melanoma
15. 6-methylguanine is bcl-2 and caspase 9/3 regulated and Fas/caspase-8 independent
16. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
17. 6-benzylguanine: A clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair
18. 6-alkylguanine-DNA alkyltransferase (ATase) depletion
19. Phase I trial of temozolomide using an extended continuous oral schedule
20. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma
21. 6-alkylguanine-DNA alkyltransferase